Huntington’s Disease (HD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Huntington’s Disease (HD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Huntington’s Disease Therapeutics market. The report identifies the key trends shaping and driving the global Huntington’s Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Huntington’s Disease Therapeutics sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Huntington’s Disease Therapeutics market. Its scope includes -
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
Summary
GlobalData, the industry analysis specialist, has released its new report, “Huntington’s Disease (HD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Huntington’s Disease Therapeutics market. The report identifies the key trends shaping and driving the global Huntington’s Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Huntington’s Disease Therapeutics sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Huntington’s Disease Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Huntington’s Disease Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Huntington’s Disease Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Huntington’s Disease Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Huntington’s Disease Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Huntington’s Disease Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Huntington’s Disease Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Huntington’s Disease Therapeutics market landscape? - Identify, understand and capitalize.
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 HUNTINGTON’S DISEASE (HD) THERAPEUTICS - INTRODUCTION
2.1 Disease Overview
2.1.1 Genetic Mutation
2.2 Etiology and Pathophysiology
2.3 Epidemiology
2.3.1 The US -
2.3.2 The UK -
2.3.3 Germany -
2.3.4 Spain -
2.3.5 Italy -
2.3.6 France -
2.3.7 Japan -
2.3.8 Pharmaco-economic Burden
2.3.9 Quality of Life (QoL)
2.3.10 Mortality and Morbidity
2.3.11 Sex -
2.3.12 Age -
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 History
2.5.2 Examination
2.6 Treatment and Management Pattern
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance
3 HUNTINGTON’S DISEASE THERAPEUTICS - MARKET CHARACTERIZATION
3.1 Overview
3.2 Huntington’s Disease Therapeutics Market Size (2005-2010) - Global
3.3 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - Global
3.4 Huntington’s Disease Therapeutics Market Size (2005-2010) - The US
3.5 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - The US
3.6 Huntington’s Disease Therapeutics Market Size (2005-2010) - France
3.7 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - France
3.8 Huntington’s Disease Therapeutics Market Size (2005-2010) - Germany
3.9 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - Germany
3.10 Huntington’s Disease Therapeutics Market Size (2005-2010) - Italy
3.11 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - Italy
3.12 Huntington’s Disease Therapeutics Market Size (2005-2010) - Spain
3.13 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - Spain
3.14 Huntington’s Disease Therapeutics Market Size (2005-2010) - The UK
3.15 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - The UK
3.16 Huntington’s Disease Therapeutics Market Size (2005-2010) - Japan
3.17 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - Japan
3.18 Drivers and Barriers for the Huntington’s Disease Therapeutics Market
3.18.1 Drivers for the Huntington’s Disease Therapeutics Market
3.18.2 Restraints for the Huntington’s Disease Therapeutics Market
3.19 Opportunity and Unmet Need Analysis
3.20 Key Takeaway
4 HUNTINGTON’S DISEASE THERAPEUTICS - COMPETITIVE ASSESSMENT
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Huntington’s disease Therapeutics Market
4.3.1 Tetrabenazine
4.4 Key Takeaway
5 HUNTINGTON’S DISEASE THERAPEUTICS - PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Huntington’s Disease Therapeutics Pipeline - Pipeline by Phases of Development
5.3.1 Huntington’s Disease Therapeutics - Phase III Pipeline
5.3.2 Huntington’s Disease Therapeutics - Phase II Pipeline
5.3.3 Huntington’s Disease Therapeutics - Phase I Pipeline
5.3.4 Huntington’s Disease Therapeutics - Pre-clinical Pipeline
5.3.5 Huntington’s Disease Therapeutics - Discovery Pipeline
5.4 Huntington’s Disease Therapeutics Market - Pipeline by Mechanism of Action
5.5 Technology Trends Analytic Framework
5.6 Huntington’s disease Therapeutics - Promising Drugs Under Clinical Development
5.7 Molecule Profile for Promising Drugs under Clinical Development
5.7.1 HD-02 (creatine monohydrate)
5.7.2 Huntexil (pridopidine)
5.8 Key Takeaway
6 HUNTINGTON’S DISEASE THERAPEUTICS - CLINICAL TRIALS MAPPING
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Clinical Trials by Overall Sponsors
6.6 Top Companies Participating in Therapeutics Clinical Trials
7 HUNTINGTON’S DISEASE THERAPEUTICS - STRATEGIC ASSESSMENT
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
7.3 Huntington’s Disease Therapeutics - Implications for Future Market Competition
8 HUNTINGTON’S DISEASE THERAPEUTICS - FUTURE PLAYERS
8.1 Introduction
8.2 Company Profiles
8.2.1 Valeant Pharmaceuticals
8.2.2 Avicena Group
8.2.3 NeuroSearch A/S
8.3 Other Companies in HD Therapeutics Market
9 HUNTINGTON’S DISEASE THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS
10 HUNTINGTON’S DISEASE THERAPEUTICS - APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
LIST OF TABLES
Table 1: Huntington’s Disease Clinical Features
Table 2: Medication Used to Suppress Chorea
Table 3: Huntington’s Disease Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 4: Huntington’s Disease Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Table 5: Huntington’s Disease Therapeutics Market, the US, Revenue ($m), 2005 - 2010
Table 6: Huntington’s Disease Therapeutics Market, the US, Forecast ($m), 2010 - 2018
Table 7: Huntington’s Disease Therapeutics Market, France, Revenue ($m), 2005 - 2010
Table 8: Huntington’s Disease Therapeutics Market, France, Forecast ($m), 2010 - 2018
Table 9: Huntington’s Disease Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Table 10: Huntington’s Disease Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Table 11: Huntington’s Disease Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Table 12: Huntington’s Disease Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Table 13: Huntington’s Disease Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Table 14: Huntington’s Disease Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Table 15: Huntington’s Disease Therapeutics Market, the UK, Revenue ($m), 2005 - 2010
Table 16: Huntington’s Disease Therapeutics Market, the UK, Forecast ($m), 2010 - 2018
Table 17: Huntington’s Disease Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Table 18: Huntington’s Disease Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Table 19: Treatment Emergent Adverse Reactions in Patients Treated with Xenazine Compared to Placebo
Table 20: Huntington’s Disease Therapeutics - Phase III Pipeline, 2011
Table 21: Huntington’s Disease Therapeutics - Phase II Pipeline, 2011
Table 22: Huntington’s Disease Therapeutics - Phase I Pipeline, 2011
Table 23: Huntington’s Disease Therapeutics Pre-clinical Pipeline, 2011
Table 24: Huntington’s Disease Therapeutics - Discovery Pipeline, 2011
Table 25: Huntington’s Disease Therapeutics - Most Promising Drugs Under Clinical Development, 2011
Table 26: Huntington’s Disease Therapeutics, Clinical Trials by Region, 2011
Table 27: Huntington’s Disease Therapeutics, Clinical Trials by Phase, 2011
Table 28: Huntington’s Disease Therapeutics, Clinical Trials by Trial Status, 2011
Table 29: Huntington’s Disease Therapeutics, Clinical Trials by Prominent Sponsors, 2011
Table 30: Huntington’s Disease Therapeutics, Clinical Trials by Overall Sponsors, 2011
Table 31: Huntington’s Disease Therapeutics, Clinical Trials by Top Companies, 2011
Table 32: Valeant, CNS Pipeline, 2011
Table 33: Avicena, CNS Pipeline, 2011
Table 34: Avicena, HD Pipeline, 2011
Table 35: Neurosearch A/S, CNS Pipeline, 2011
Table 36: Neurosearch A/S, HD Pipeline, 2011
Table 37: Huntington’s Disease Therapeutics Market - Future Players, 2011
Table 38: Huntington’s Disease Therapeutics, Global, Deals, 2009-2011
LIST OF FIGURES
Figure 1: Single Striatal Neurons Transfected with a Disease-Associated Version of Huntington
Figure 2: HD Human Pedigree
Figure 3: Classification of the Trinucleotide Repeat and Resulting Disease Status
Figure 4: Severity of Huntington’s Disease Neuropathology, Grading (0-4)
Figure 5: Affected Brain Regions in Huntington’s Disease
Figure 6: Reported Prevalences of Behavioral and Psychiatric Symptoms in Huntington's Disease
Figure 7: Brain MRI Scan of a Patient with Huntington’s Disease
Figure 8: Drug Treatment for Huntington’s Disease
Figure 9: Referral Pathway Huntington’s Disease
Figure 10: Huntington’s Disease Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 11: Huntington’s Disease Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Figure 12: Huntington’s Disease Therapeutics Market, the US, Revenue ($m), 2005 - 2010
Figure 13: Huntington’s Disease Therapeutics Market, the US, Forecast ($m), 2010 - 2018
Figure 14: Huntington’s Disease Therapeutics Market, France, Revenue ($m), 2005 - 2010
Figure 15: Huntington’s Disease Therapeutics Market, France, Forecast ($m), 2010 - 2018
Figure 16: Huntington’s Disease Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Figure 17: Huntington’s Disease Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Figure 18: Huntington’s Disease Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Figure 19: Huntington’s Disease Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Figure 20: Huntington’s Disease Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Figure 21: Huntington’s Disease Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Figure 22: Huntington’s Disease Therapeutics Market, the UK, Revenue ($m), 2005 - 2010
Figure 23: Huntington’s Disease Therapeutics Market, the UK, Forecast ($m), 2010 - 2018
Figure 24: Huntington’s Disease Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Figure 25: Huntington’s Disease Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Figure 26: Opportunity and Unmet Need in the Huntington’s Disease Therapeutics Market
Figure 27: Strategic Competitor Assessment of the Major Marketed Products in Huntington’s Disease, 2011
Figure 28: Huntington’s Disease Therapeutics Pipeline by Phase of Development (%), 2011
Figure 29: Huntington’s Disease Therapeutics, Pipeline by Mechanism of Action (%), 2011
Figure 30: Huntington’s Disease Therapeutics - Technology Trends Analytics Framework, 2011
Figure 31: Huntington’s Disease Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 32: Huntington’s Disease Therapeutics, Clinical Trials by Region, 2011
Figure 33: Huntington’s Disease Therapeutics, Clinical Trials by Phase, 2011
Figure 34: Huntington’s Disease Therapeutics, Clinical Trials by Trial Status, 2011
Figure 35: Huntington’s Disease Therapeutics, Clinical Trials by Prominent Sponsors, 2011
Figure 36: Huntington’s Disease Therapeutics, Clinical Trials by Overall Sponsors, 2011
Figure 37: Huntington’s Disease Therapeutics, Clinical Trials by Top Companies, 2011
Figure 38: Huntington’s Disease Therapeutics Market, Drivers and Restraints, 2011
Figure 39: Implications for Future Market Competition in the Huntington’s Disease Market, 2011
Figure 40: Huntington’s Disease Therapeutics Market - Pipeline by Company, 2011
Figure 41: GlobalData Market Forecasting Model
COMPANIES MENTIONED
Valeant Pharmaceuticals
Avicena Group
NeuroSearch A/S
1.1 List of Tables
1.2 List of Figures
2 HUNTINGTON’S DISEASE (HD) THERAPEUTICS - INTRODUCTION
2.1 Disease Overview
2.1.1 Genetic Mutation
2.2 Etiology and Pathophysiology
2.3 Epidemiology
2.3.1 The US -
2.3.2 The UK -
2.3.3 Germany -
2.3.4 Spain -
2.3.5 Italy -
2.3.6 France -
2.3.7 Japan -
2.3.8 Pharmaco-economic Burden
2.3.9 Quality of Life (QoL)
2.3.10 Mortality and Morbidity
2.3.11 Sex -
2.3.12 Age -
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 History
2.5.2 Examination
2.6 Treatment and Management Pattern
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance
3 HUNTINGTON’S DISEASE THERAPEUTICS - MARKET CHARACTERIZATION
3.1 Overview
3.2 Huntington’s Disease Therapeutics Market Size (2005-2010) - Global
3.3 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - Global
3.4 Huntington’s Disease Therapeutics Market Size (2005-2010) - The US
3.5 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - The US
3.6 Huntington’s Disease Therapeutics Market Size (2005-2010) - France
3.7 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - France
3.8 Huntington’s Disease Therapeutics Market Size (2005-2010) - Germany
3.9 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - Germany
3.10 Huntington’s Disease Therapeutics Market Size (2005-2010) - Italy
3.11 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - Italy
3.12 Huntington’s Disease Therapeutics Market Size (2005-2010) - Spain
3.13 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - Spain
3.14 Huntington’s Disease Therapeutics Market Size (2005-2010) - The UK
3.15 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - The UK
3.16 Huntington’s Disease Therapeutics Market Size (2005-2010) - Japan
3.17 Huntington’s Disease Therapeutics Market Forecast (2010-2018) - Japan
3.18 Drivers and Barriers for the Huntington’s Disease Therapeutics Market
3.18.1 Drivers for the Huntington’s Disease Therapeutics Market
3.18.2 Restraints for the Huntington’s Disease Therapeutics Market
3.19 Opportunity and Unmet Need Analysis
3.20 Key Takeaway
4 HUNTINGTON’S DISEASE THERAPEUTICS - COMPETITIVE ASSESSMENT
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Huntington’s disease Therapeutics Market
4.3.1 Tetrabenazine
4.4 Key Takeaway
5 HUNTINGTON’S DISEASE THERAPEUTICS - PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Huntington’s Disease Therapeutics Pipeline - Pipeline by Phases of Development
5.3.1 Huntington’s Disease Therapeutics - Phase III Pipeline
5.3.2 Huntington’s Disease Therapeutics - Phase II Pipeline
5.3.3 Huntington’s Disease Therapeutics - Phase I Pipeline
5.3.4 Huntington’s Disease Therapeutics - Pre-clinical Pipeline
5.3.5 Huntington’s Disease Therapeutics - Discovery Pipeline
5.4 Huntington’s Disease Therapeutics Market - Pipeline by Mechanism of Action
5.5 Technology Trends Analytic Framework
5.6 Huntington’s disease Therapeutics - Promising Drugs Under Clinical Development
5.7 Molecule Profile for Promising Drugs under Clinical Development
5.7.1 HD-02 (creatine monohydrate)
5.7.2 Huntexil (pridopidine)
5.8 Key Takeaway
6 HUNTINGTON’S DISEASE THERAPEUTICS - CLINICAL TRIALS MAPPING
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Clinical Trials by Overall Sponsors
6.6 Top Companies Participating in Therapeutics Clinical Trials
7 HUNTINGTON’S DISEASE THERAPEUTICS - STRATEGIC ASSESSMENT
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
7.3 Huntington’s Disease Therapeutics - Implications for Future Market Competition
8 HUNTINGTON’S DISEASE THERAPEUTICS - FUTURE PLAYERS
8.1 Introduction
8.2 Company Profiles
8.2.1 Valeant Pharmaceuticals
8.2.2 Avicena Group
8.2.3 NeuroSearch A/S
8.3 Other Companies in HD Therapeutics Market
9 HUNTINGTON’S DISEASE THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS
10 HUNTINGTON’S DISEASE THERAPEUTICS - APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
LIST OF TABLES
Table 1: Huntington’s Disease Clinical Features
Table 2: Medication Used to Suppress Chorea
Table 3: Huntington’s Disease Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 4: Huntington’s Disease Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Table 5: Huntington’s Disease Therapeutics Market, the US, Revenue ($m), 2005 - 2010
Table 6: Huntington’s Disease Therapeutics Market, the US, Forecast ($m), 2010 - 2018
Table 7: Huntington’s Disease Therapeutics Market, France, Revenue ($m), 2005 - 2010
Table 8: Huntington’s Disease Therapeutics Market, France, Forecast ($m), 2010 - 2018
Table 9: Huntington’s Disease Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Table 10: Huntington’s Disease Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Table 11: Huntington’s Disease Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Table 12: Huntington’s Disease Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Table 13: Huntington’s Disease Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Table 14: Huntington’s Disease Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Table 15: Huntington’s Disease Therapeutics Market, the UK, Revenue ($m), 2005 - 2010
Table 16: Huntington’s Disease Therapeutics Market, the UK, Forecast ($m), 2010 - 2018
Table 17: Huntington’s Disease Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Table 18: Huntington’s Disease Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Table 19: Treatment Emergent Adverse Reactions in Patients Treated with Xenazine Compared to Placebo
Table 20: Huntington’s Disease Therapeutics - Phase III Pipeline, 2011
Table 21: Huntington’s Disease Therapeutics - Phase II Pipeline, 2011
Table 22: Huntington’s Disease Therapeutics - Phase I Pipeline, 2011
Table 23: Huntington’s Disease Therapeutics Pre-clinical Pipeline, 2011
Table 24: Huntington’s Disease Therapeutics - Discovery Pipeline, 2011
Table 25: Huntington’s Disease Therapeutics - Most Promising Drugs Under Clinical Development, 2011
Table 26: Huntington’s Disease Therapeutics, Clinical Trials by Region, 2011
Table 27: Huntington’s Disease Therapeutics, Clinical Trials by Phase, 2011
Table 28: Huntington’s Disease Therapeutics, Clinical Trials by Trial Status, 2011
Table 29: Huntington’s Disease Therapeutics, Clinical Trials by Prominent Sponsors, 2011
Table 30: Huntington’s Disease Therapeutics, Clinical Trials by Overall Sponsors, 2011
Table 31: Huntington’s Disease Therapeutics, Clinical Trials by Top Companies, 2011
Table 32: Valeant, CNS Pipeline, 2011
Table 33: Avicena, CNS Pipeline, 2011
Table 34: Avicena, HD Pipeline, 2011
Table 35: Neurosearch A/S, CNS Pipeline, 2011
Table 36: Neurosearch A/S, HD Pipeline, 2011
Table 37: Huntington’s Disease Therapeutics Market - Future Players, 2011
Table 38: Huntington’s Disease Therapeutics, Global, Deals, 2009-2011
LIST OF FIGURES
Figure 1: Single Striatal Neurons Transfected with a Disease-Associated Version of Huntington
Figure 2: HD Human Pedigree
Figure 3: Classification of the Trinucleotide Repeat and Resulting Disease Status
Figure 4: Severity of Huntington’s Disease Neuropathology, Grading (0-4)
Figure 5: Affected Brain Regions in Huntington’s Disease
Figure 6: Reported Prevalences of Behavioral and Psychiatric Symptoms in Huntington's Disease
Figure 7: Brain MRI Scan of a Patient with Huntington’s Disease
Figure 8: Drug Treatment for Huntington’s Disease
Figure 9: Referral Pathway Huntington’s Disease
Figure 10: Huntington’s Disease Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 11: Huntington’s Disease Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Figure 12: Huntington’s Disease Therapeutics Market, the US, Revenue ($m), 2005 - 2010
Figure 13: Huntington’s Disease Therapeutics Market, the US, Forecast ($m), 2010 - 2018
Figure 14: Huntington’s Disease Therapeutics Market, France, Revenue ($m), 2005 - 2010
Figure 15: Huntington’s Disease Therapeutics Market, France, Forecast ($m), 2010 - 2018
Figure 16: Huntington’s Disease Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Figure 17: Huntington’s Disease Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Figure 18: Huntington’s Disease Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Figure 19: Huntington’s Disease Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Figure 20: Huntington’s Disease Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Figure 21: Huntington’s Disease Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Figure 22: Huntington’s Disease Therapeutics Market, the UK, Revenue ($m), 2005 - 2010
Figure 23: Huntington’s Disease Therapeutics Market, the UK, Forecast ($m), 2010 - 2018
Figure 24: Huntington’s Disease Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Figure 25: Huntington’s Disease Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Figure 26: Opportunity and Unmet Need in the Huntington’s Disease Therapeutics Market
Figure 27: Strategic Competitor Assessment of the Major Marketed Products in Huntington’s Disease, 2011
Figure 28: Huntington’s Disease Therapeutics Pipeline by Phase of Development (%), 2011
Figure 29: Huntington’s Disease Therapeutics, Pipeline by Mechanism of Action (%), 2011
Figure 30: Huntington’s Disease Therapeutics - Technology Trends Analytics Framework, 2011
Figure 31: Huntington’s Disease Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 32: Huntington’s Disease Therapeutics, Clinical Trials by Region, 2011
Figure 33: Huntington’s Disease Therapeutics, Clinical Trials by Phase, 2011
Figure 34: Huntington’s Disease Therapeutics, Clinical Trials by Trial Status, 2011
Figure 35: Huntington’s Disease Therapeutics, Clinical Trials by Prominent Sponsors, 2011
Figure 36: Huntington’s Disease Therapeutics, Clinical Trials by Overall Sponsors, 2011
Figure 37: Huntington’s Disease Therapeutics, Clinical Trials by Top Companies, 2011
Figure 38: Huntington’s Disease Therapeutics Market, Drivers and Restraints, 2011
Figure 39: Implications for Future Market Competition in the Huntington’s Disease Market, 2011
Figure 40: Huntington’s Disease Therapeutics Market - Pipeline by Company, 2011
Figure 41: GlobalData Market Forecasting Model
COMPANIES MENTIONED
Valeant Pharmaceuticals
Avicena Group
NeuroSearch A/S
